Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of DCB-BO1301 as Add-on Therapy to Dacarbazine in Subjects With Advanced Melanoma

NCT02994498 is registered in ClinicalTrials.gov with Chung Mei Biopharma Co., Ltd as lead sponsor.

NCT NCT02994498
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02994498 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of DCB-BO1301 as Add-on Therapy to Dacarbazine in Subjects With Advanced Melanoma
Lead sponsor
Chung Mei Biopharma Co., Ltd
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 31, 2023
Completion date
December 31, 2025
Enrollment
33 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

advanced melanoma